Azenta Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Azenta de 125.6% y 0.4% por año respectivamente. Se prevé que el BPA crezca en un 118.7% al año. Se espera que la rentabilidad financiera sea de -0.7% en 3 años.

Información clave

125.6%

Tasa de crecimiento de los beneficios

118.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	18.4%
Tasa de crecimiento de los ingresos	0.4%
Rentabilidad financiera futura	-0.7%
Cobertura de analistas	Good
Última actualización	13 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

Nov 17

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:AZTA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2027	681	41	N/A	N/A	1
9/30/2026	650	2	17	N/A	6
9/30/2025	611	-23	2	N/A	6
9/30/2024	656	-164	N/A	N/A	N/A
6/30/2024	659	-156	41	76	N/A
3/31/2024	652	-152	55	91	N/A
12/31/2023	641	-17	32	71	N/A
9/30/2023	665	-13	-22	17	N/A
6/30/2023	630	-21	-56	-13	N/A
3/31/2023	597	-26	-500	-449	N/A
12/31/2022	594	-25	-581	-509	N/A
9/30/2022	555	-11	-543	-466	N/A
6/30/2022	555	-28	-530	-449	N/A
3/31/2022	551	-23	-59	16	N/A
12/31/2021	535	-29	66	122	N/A
9/30/2021	514	-29	97	150	N/A
6/30/2021	114	-69	130	175	N/A
3/31/2021	205	-53	112	156	N/A
12/31/2020	296	-37	10	56	N/A
9/30/2020	389	-26	-2	38	N/A
6/30/2020	850	41	-19	19	N/A
3/31/2020	834	28	-7	29	N/A
12/31/2019	812	16	80	110	N/A
9/30/2019	334	-61	67	91	N/A
6/30/2019	741	3	70	89	N/A
3/31/2019	710	7	56	73	N/A
12/31/2018	668	72	63	77	N/A
9/30/2018	632	68	61	74	N/A
6/30/2018	488	35	N/A	78	N/A
3/31/2018	498	47	N/A	76	N/A
12/31/2017	510	-2	N/A	81	N/A
9/30/2017	527	11	N/A	96	N/A
6/30/2017	669	56	N/A	85	N/A
3/31/2017	634	47	N/A	82	N/A
12/31/2016	600	-51	N/A	71	N/A
9/30/2016	434	-85	N/A	40	N/A
6/30/2016	549	-73	N/A	38	N/A
3/31/2016	546	-74	N/A	39	N/A
12/31/2015	550	12	N/A	28	N/A
9/30/2015	553	14	N/A	44	N/A
6/30/2015	529	8	N/A	35	N/A
3/31/2015	502	-3	N/A	23	N/A
12/31/2014	489	-3	N/A	48	N/A
9/30/2014	483	1	N/A	54	N/A
6/30/2014	471	3	N/A	65	N/A
3/31/2014	464	10	N/A	73	N/A
12/31/2013	448	5	N/A	58	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que AZTA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que AZTA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que AZTA sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (0.4% al año) de AZTA crezcan más despacio que el mercado de US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 0.4% al año) de AZTA crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: AZTA se prevé que no sea rentable en 3 años.

Azenta Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 14%

Price target decreased by 7.2% to US$56.60

Price target decreased by 7.2% to US$58.25

Consensus EPS estimates fall by 29%

Forecast to breakeven in 2026

No longer forecast to breakeven

Recent updates

Independent Director recently bought US$495k worth of stock

Consensus revenue estimates decrease by 14%

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

Price target decreased by 7.2% to US$56.60

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Full year 2024 earnings: EPS misses analyst expectations

Azenta, Inc. Announces Chief Financial Officer Changes

Azenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024

Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test

Azenta: Life Science Play Is Not Coming To Life

Azenta, Inc. Announces Management Changes

Price target decreased by 7.2% to US$58.25

Consensus EPS estimates fall by 29%

Forecast to breakeven in 2026

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024

Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon

Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024

Stephen Schwartz to Retire as CEO of Azenta, Inc

Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024

Should You Investigate Azenta, Inc. (NASDAQ:AZTA) At US$52.18?

Now 20% overvalued

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Consensus EPS estimates fall by 20%

New major risk - Revenue and earnings growth

Senior VP notifies of intention to sell stock

Consensus EPS estimates fall by 19%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Azenta, Inc. Announces the Launch of the BioArc Ultra

Price target increased by 9.9% to US$72.00

Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc

Subdued Growth No Barrier To Azenta, Inc.'s (NASDAQ:AZTA) Price

Azenta, Inc., Annual General Meeting, Jan 30, 2024

Key Executive notifies of intention to sell stock

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 20%

Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023

Is There An Opportunity With Azenta, Inc.'s (NASDAQ:AZTA) 31% Undervaluation?

Politan Capital Provides Information to the Shareholders

Consensus EPS estimates upgraded to US$0.39 loss

Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023

Politan Capital Management Engages in Discussions with Azenta

Politan Capital Management Engages in Discussions with Azenta

At US$50.66, Is It Time To Put Azenta, Inc. (NASDAQ:AZTA) On Your Watch List?

Now 23% undervalued

New minor risk - Insider selling

Insider recently sold US$407k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Azenta, Inc. Revises Revenue Guidance for the Full Year of 2023

Estimating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)

Consensus EPS estimates upgraded to US$0.49 loss

Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023

Now 20% undervalued

Independent Chairman notifies of intention to sell stock

Is Azenta, Inc. (NASDAQ:AZTA) Potentially Undervalued?

Price target decreased by 13% to US$52.50

Forecast breakeven date pushed back to 2025

Consensus revenue estimates decrease by 11%

Revenue Downgrade: Here's What Analysts Forecast For Azenta, Inc. (NASDAQ:AZTA)

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023